Developer docs
API playgroundTry for free, no card

Search company profiles

Pathalys Pharma

Full company profile

uuid0000wyy

Namestring
Pathalys Pharma
Legal namestring
Pathalys Pharma, Inc.
Websiteurl
pathalys.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company founded in March 2022 and headquartered in Research Triangle Park, North Carolina. The company is focused on developing therapeutics that improve the management of late-stage chronic kidney disease (CKD), with a primary emphasis on secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis for end-stage kidney disease. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group, with Neal Fowler (former CEO of Liquidia Technologies) serving as CEO and BT Slingsby (Managing Partner of Catalys Pacific) as Executive Chairman.

The company's core product is upacicalcet, a novel intravenous small molecule calcimimetic in-licensed from EA Pharma (a subsidiary of Eisai) for worldwide development and commercialization rights outside of Japan and Asia. Upacicalcet activates the calcium-sensing receptor (CaSR) at the highest calcium set point among calcimimetics tested, and is administered as a bolus IV injection at the end of hemodialysis sessions via a pre-filled syringe. It is currently being evaluated in the PATH Phase 3 program, consisting of two identical randomized, double-blind, placebo-controlled trials of approximately 375 patients each (2:1 randomization) with a primary endpoint of ≥30% reduction in intact parathyroid hormone (iPTH). The drug was approved in Japan in 2021 under the brand name UPASITA, with Phase 3 data demonstrating 80.6% of patients achieving ≥30% iPTH reduction, 67% achieving mean iPTH 60-240 pg/mL, and lower adverse event rates (1.9% upper GI AEs vs 6.0% placebo; 1.9% hypocalcemia) versus the Japanese comparator.

Pathalys is pre-revenue and does not yet market any approved products. Its forward business model is direct commercialization of upacicalcet to dialysis providers and nephrology healthcare providers upon FDA approval, leveraging clinical trial relationships with major dialysis operators (notably DaVita, a co-founder). The company retains manufacturing, regulatory, and primary commercialization responsibilities while contracting operational execution of its Phase 3 program to Launch Therapeutics. Cumulative financing raised since founding is approximately $266 million across a 2022 seed, a January 2023 $150 million financing led by Abingworth (part of Carlyle) with OrbiMed, and an August 2024 oversubscribed $105 million Series B led by TCGX with JP Morgan Life Sciences Private Capital and Samsara BioCapital. The company operates with a small leadership team and uses Launch Therapeutics and other service providers to scale clinical operations.

Short descriptiontext

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic, for treating secondary hyperparathyroidism in end-stage kidney disease patients receiving hemodialysis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
nephrology therapeutics, chronic kidney disease, calcimimetic drugs, secondary hyperparathyroidism, hemodialysis treatment
Industry3 codes
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Nephrology Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Once upacicalcet receives FDA approval, Pathalys plans to commercialize the drug directly, selling to dialysis providers and healthcare systems. The company retains worldwide commercial rights to upacicalcet outside Japan and Asia.

pathalys.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease on hemodialysis. The drug is administered as a bolus IV injection at the end of dialysis sessions via pre-filled syringe. Pathalys holds worldwide commercial rights outside Japan and Asia, where upacicalcet is already approved under the brand name UPASITA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 67% of patients achieved mean iPTH between 60-240 pg/mL (vs 8% placebo)
+3 more records
Product overview1 text field

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company operates a multi-asset strategy focused on end-stage kidney disease, with its lead product upacicalcet (designated PLS240 in clinical trials) being evaluated in the PATH Phase 3 clinical program. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group and holds worldwide commercial rights to upacicalcet outside Japan and Asia, where it is approved under the brand name UPASITA®.

Product and service1 record
1Upacicalcet
CategoryCalcimimetic drug / Nephrology therapeutic
Description

Upacicalcet is a novel intravenous small molecule calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease patients receiving hemodialysis. Administered as a bolus IV injection at the end of dialysis sessions via pre-filled syringe, it activates the calcium-sensing receptor to reduce parathyroid hormone (PTH) levels with potential for better tolerability compared to existing therapies.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-18
Description

Launch Therapeutics serves as the operational lead for execution and management of Pathalys' two Phase 3 clinical trials for upacicalcet. Launch Tx brings clinical development resources and expertise to accelerate the path to regulatory approval. Pathalys retains primary responsibility for manufacturing, FDA regulatory interactions, and commercialization. Launch Tx is backed by Carlyle and Abingworth.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-03-01
Description

EA Pharma (subsidiary of Eisai) granted Pathalys an exclusive license to develop and commercialize upacicalcet worldwide outside of Japan and Asia. Upacicalcet was approved in Japan in 2021 under the brand name UPASITA.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Markets Sensipar/Mimpara (cinacalcet, oral calcimimetic) and Parsabiv (etelcalcetide, IV calcimimetic) — the two established calcimimetics for SHPT in dialysis patients. Direct incumbent competitor to upacicalcet across both oral and IV segments of the same patient population.

TypeDirect peer
Description

Late-stage nephrology biopharma focused on CKD and dialysis-related indications (e.g., tenapanor for hyperphosphatemia). Comparable business model as a small, late-stage clinical biopharma targeting the same dialysis patient population.

TypeDirect peer
Description

CKD-focused biopharma developing vadadustat for anemia in CKD/dialysis; same end-customer (nephrologists and dialysis providers) and similar late-stage commercial build-out dynamics in the dialysis channel.

TypeDirect peer
Description

Developed Korsuva (difelikefalin) for CKD-associated pruritus in hemodialysis patients — comparable late-stage biopharma with a dialysis-channel commercialization focus and similar payer/provider economics.

TypeBroad incumbent
Description

Established nephrology/specialty pharma company with iron deficiency franchise (Injectafer) and broader CKD/cardio-renal portfolio. Pathalys' COO Patrick Treanor was previously President US of Vifor, indicating direct comparability on commercial channels and customer base.

TypeBroad incumbent
Description

Markets tolvaptan (Jynarque) for autosomal dominant polycystic kidney disease and has broader renal/cardiorenal portfolio. Comparable nephrology-focused commercial channel serving the same dialysis and CKD prescriber base.

TypeEmerging player
Description

Clinical-stage biopharma developing aldosterone synthase inhibitors for CKD and resistant hypertension; co-created by Catalys Pacific (same founder as Pathalys) — directly comparable as a sister CKD company with similar investor base and development philosophy.

TypeEmerging player
Description

Rare kidney disease biopharma (acquired by Novartis for $3.5B in 2023) developing atrasentan and zigakibart for IgA nephropathy and other CKD indications. Comparable late-stage nephrology biopharma business model and CKD focus.

9EA Pharma / Eisai
TypeBroad incumbent
Description

Original developer and Japan/Asia marketer of upacicalcet (UPASITA); Pathalys' licensor. Comparable as the reference commercial benchmark for the asset in a different geography and a related pharmaceutical manufacturer.

TypeEmerging player
Description

Small clinical-stage biopharma focused on CNS and specialty indications; comparable scale and late-stage development profile, with adjacent nephrology-relevant experience in specialty pharma commercialization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pathalys Pharma

Nephrology Pharmaceuticalspathalys.com

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic, for treating secondary hyperparathyroidism in end-stage kidney disease patients receiving hemodialysis.

What Pathalys Pharma does

Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company founded in March 2022 and headquartered in Research Triangle Park, North Carolina. The company is focused on developing therapeutics that improve the management of late-stage chronic kidney disease (CKD), with a primary emphasis on secondary hyperparathyroidism (SHPT) in patients receiving hemodialysis for end-stage kidney disease. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group, with Neal Fowler (former CEO of Liquidia Technologies) serving as CEO and BT Slingsby (Managing Partner of Catalys Pacific) as Executive Chairman.

The company's core product is upacicalcet, a novel intravenous small molecule calcimimetic in-licensed from EA Pharma (a subsidiary of Eisai) for worldwide development and commercialization rights outside of Japan and Asia. Upacicalcet activates the calcium-sensing receptor (CaSR) at the highest calcium set point among calcimimetics tested, and is administered as a bolus IV injection at the end of hemodialysis sessions via a pre-filled syringe. It is currently being evaluated in the PATH Phase 3 program, consisting of two identical randomized, double-blind, placebo-controlled trials of approximately 375 patients each (2:1 randomization) with a primary endpoint of ≥30% reduction in intact parathyroid hormone (iPTH). The drug was approved in Japan in 2021 under the brand name UPASITA, with Phase 3 data demonstrating 80.6% of patients achieving ≥30% iPTH reduction, 67% achieving mean iPTH 60-240 pg/mL, and lower adverse event rates (1.9% upper GI AEs vs 6.0% placebo; 1.9% hypocalcemia) versus the Japanese comparator.

Pathalys is pre-revenue and does not yet market any approved products. Its forward business model is direct commercialization of upacicalcet to dialysis providers and nephrology healthcare providers upon FDA approval, leveraging clinical trial relationships with major dialysis operators (notably DaVita, a co-founder). The company retains manufacturing, regulatory, and primary commercialization responsibilities while contracting operational execution of its Phase 3 program to Launch Therapeutics. Cumulative financing raised since founding is approximately $266 million across a 2022 seed, a January 2023 $150 million financing led by Abingworth (part of Carlyle) with OrbiMed, and an August 2024 oversubscribed $105 million Series B led by TCGX with JP Morgan Life Sciences Private Capital and Samsara BioCapital. The company operates with a small leadership team and uses Launch Therapeutics and other service providers to scale clinical operations.

Pathalys Pharma firmographics

Firmographics
Name
Pathalys Pharma
Legal name
Pathalys Pharma, Inc.
Website
https://pathalys.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic, for treating secondary hyperparathyroidism in end-stage kidney disease patients receiving hemodialysis.
Ownership category
akta.pro rank

Pathalys Pharma industry classification

Industry
Product category
Nephrology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Nephrology therapeutics
  • Chronic kidney disease
  • Calcimimetic drugs
  • Secondary hyperparathyroidism
  • Hemodialysis treatment

Where Pathalys Pharma is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pathalys Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Pharmaceutical Product Sales: Once upacicalcet receives FDA approval, Pathalys plans to commercialize the drug directly, selling to dialysis providers and healthcare systems. The company retains worldwide commercial rights to upacicalcet outside Japan and Asia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Pathalys Pharma product offering

Product offering

Core offering

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease on hemodialysis. The drug is administered as a bolus IV injection at the end of dialysis sessions via pre-filled syringe. Pathalys holds worldwide commercial rights outside Japan and Asia, where upacicalcet is already approved under the brand name UPASITA.

Product overview

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company operates a multi-asset strategy focused on end-stage kidney disease, with its lead product upacicalcet (designated PLS240 in clinical trials) being evaluated in the PATH Phase 3 clinical program. Pathalys was co-founded by Catalys Pacific and DaVita Venture Group and holds worldwide commercial rights to upacicalcet outside Japan and Asia, where it is approved under the brand name UPASITA®.

Differentiator

Problem solved

Functional benefit

Products and services

  • Upacicalcet Upacicalcet is a novel intravenous small molecule calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in end-stage kidney disease patients receiving hemodialysis. Administered as a bolus IV injection at the end of dialysis sessions via pre-filled syringe, it activates the calcium-sensing receptor to reduce parathyroid hormone (PTH) levels with potential for better tolerability compared to existing therapies.

Quantifiable outcome

  • 67% of patients achieved mean iPTH between 60-240 pg/mL (vs 8% placebo)
  • +3 more outcomes

Companies that use Pathalys Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Pathalys Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pathalys Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Launch TherapeuticscoreStrategic or Co-development Partner · 18 January 2023Launch Therapeutics serves as the operational lead for execution and management of Pathalys' two Phase 3 clinical trials for upacicalcet. Launch Tx brings clinical development resources and expertise to accelerate the path to regulatory approval. Pathalys retains primary responsibility for manufacturing, FDA regulatory interactions, and commercialization. Launch Tx is backed by Carlyle and Abingworth.
  • EA PharmacoreOEM/ Whitelabel/ Licensing Partner · 1 March 2022EA Pharma (subsidiary of Eisai) granted Pathalys an exclusive license to develop and commercialize upacicalcet worldwide outside of Japan and Asia. Upacicalcet was approved in Japan in 2021 under the brand name UPASITA.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Pathalys Pharma competitors and assessment

Company assessment

Direct peers

  • Amgen: Markets Sensipar/Mimpara (cinacalcet, oral calcimimetic) and Parsabiv (etelcalcetide, IV calcimimetic) — the two established calcimimetics for SHPT in dialysis patients. Direct incumbent competitor to upacicalcet across both oral and IV segments of the same patient population.
  • Ardelyx: Late-stage nephrology biopharma focused on CKD and dialysis-related indications (e.g., tenapanor for hyperphosphatemia). Comparable business model as a small, late-stage clinical biopharma targeting the same dialysis patient population.
  • Akebia Therapeutics: CKD-focused biopharma developing vadadustat for anemia in CKD/dialysis; same end-customer (nephrologists and dialysis providers) and similar late-stage commercial build-out dynamics in the dialysis channel.
  • Cara Therapeutics: Developed Korsuva (difelikefalin) for CKD-associated pruritus in hemodialysis patients — comparable late-stage biopharma with a dialysis-channel commercialization focus and similar payer/provider economics.

Broad incumbents

  • Vifor Pharma: Established nephrology/specialty pharma company with iron deficiency franchise (Injectafer) and broader CKD/cardio-renal portfolio. Pathalys' COO Patrick Treanor was previously President US of Vifor, indicating direct comparability on commercial channels and customer base.
  • Otsuka Pharmaceutical: Markets tolvaptan (Jynarque) for autosomal dominant polycystic kidney disease and has broader renal/cardiorenal portfolio. Comparable nephrology-focused commercial channel serving the same dialysis and CKD prescriber base.
  • EA Pharma / Eisai: Original developer and Japan/Asia marketer of upacicalcet (UPASITA); Pathalys' licensor. Comparable as the reference commercial benchmark for the asset in a different geography and a related pharmaceutical manufacturer.

Emerging players

  • Mineralys Therapeutics: Clinical-stage biopharma developing aldosterone synthase inhibitors for CKD and resistant hypertension; co-created by Catalys Pacific (same founder as Pathalys) — directly comparable as a sister CKD company with similar investor base and development philosophy.
  • Chinook Therapeutics (Novartis): Rare kidney disease biopharma (acquired by Novartis for $3.5B in 2023) developing atrasentan and zigakibart for IgA nephropathy and other CKD indications. Comparable late-stage nephrology biopharma business model and CKD focus.
  • Trevena: Small clinical-stage biopharma focused on CNS and specialty indications; comparable scale and late-stage development profile, with adjacent nephrology-relevant experience in specialty pharma commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pathalys Pharma social profiles

Digital presence

Pathalys Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pathalys Pharma leadership team

Management profile

Number of profiles

Profiles14 records

Pathalys Pharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pathalys Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathalys Pharma

What does Pathalys Pharma do?

Pathalys Pharma is a private, late-stage clinical biopharmaceutical company developing upacicalcet, a novel intravenous calcimimetic for the treatment of secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease on hemodialysis. The drug is administered as a bolus IV injection at the end of dialysis sessions via pre-filled syringe. Pathalys holds worldwide commercial rights outside Japan and Asia, where upacicalcet is already approved under the brand name UPASITA.

Is Pathalys Pharma a public or private company?

Pathalys Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pathalys Pharma founded?

Pathalys Pharma was founded in 2022. It employs 11 to 50 people.

Where is Pathalys Pharma based?

Pathalys Pharma is headquartered in Raleigh, United States, in the North America region.

How does Pathalys Pharma make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Pathalys Pharma's main competitors?

Direct peers on record are Amgen, Ardelyx, Akebia Therapeutics and Cara Therapeutics. Broad incumbents are Vifor Pharma, Otsuka Pharmaceutical and EA Pharma / Eisai. Emerging players are Mineralys Therapeutics, Chinook Therapeutics (Novartis) and Trevena.

Does Pathalys Pharma have an API?

No public API is recorded for Pathalys Pharma.

What industry is Pathalys Pharma in?

Pathalys Pharma's product category is Nephrology Pharmaceuticals. Its primary akta.pro industry code is HLAGAHAA, Small-Molecule API Process Development & Route Scouting, with a secondary code of HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRESSBEEPathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026 ...Middle EastPathalys Pharma presented positive data from pivotal Phase 3 studies of upacicalcet at ASN Kidney Week 2026. In PATH-1 and PATH-2, upacicalcet met primary and key secondary endpoints, reducing parathyroid hormone in patients with end-stage kidney disease and secondary hyperparathyroidism on hemodialysis, and also lowered FGF23 and bone turnover markers.American City Business JournalsNext steps for Pathalys Pharma after $105 million Series BPathalys Pharma closed an oversubscribed $105 million Series B round led by TCGX, giving it cash runway to support its lead product through commercial launch. The company has completed enrollment in two Phase 3 studies and plans to file a new drug application with the FDA, with a data readout expected later this year.FinSMEsPathalys Pharma Raises $105M in Series B FundingPathalys Pharma raised $105M in Series B funding led by TCGX, with participation from JP Morgan Life Sciences Private Capital and others. The company will use the funds to finalize two upacicalcet clinical trials, execute the NDA filing with the FDA, and accelerate preapproval commercialization preparations.PR NewswirePathalys Pharma and Launch Therapeutics Announce First Patient Enrolled Ahead of Schedule in Pivotal Phase 3 Program for Upacicalcet in Patients Receiving HemodialysisPathalys Pharma and Launch Therapeutics have enrolled the first patient ahead of schedule in the PATH Phase 3 clinical program evaluating upacicalcet for treating secondary hyperparathyroidism in end-stage kidney disease patients on hemodialysis. The PATH program consists of two identical Phase 3 trialsrandomizing approximately 375 patients each (2:1 to upacicalcet or placebo), with upacicalcet administered as a bolus IV injection at the end of dialysis sessions. Upacicalcet is a novel calcimimetic already approved in Japan in 2021, and the companies aim to accelerate its registration in the US.FinSMEsPathalys Pharma Raises $150M in Secured Product Financing and EquityPathalys Pharma raised $150M in secured product financing and equity, led by Abingworth with Carlyle, OrbiMed, and founding investors. The funds will support phase 3 trials and pre-commercialization for upacicalcet, a calcimimetic for secondary hyperparathyroidism in hemodialysis patients. Launch Therapeutics announced a collaboration to advance these trials.Venture Capital Access OnlinePathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma has secured $150 million in product financing and equity led by Abingworth to support phase 3 clinical trials of its treatment upacicalcet for secondary hyperparathyroidism. The collaboration with Launch Therapeutics aims to advance upacicalcet through significant clinical trials, with both companies contributing their resources toward this goal. Pathalys retains worldwide rights to the product, excluding Japan and Asia, and is positioned to complete its regulatory and commercialization efforts for upacicalcet.PathalysPathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma raised $150 million in secured product financing and equity, led by Abingworth, to fund pivotal Phase 3 trials for its drug upacicalcet. The company also announced a strategic collaboration with Launch Therapeutics to manage the clinical development of upacicalcet for secondary hyperparathyroidism in hemodialysis patients.BioSpacePathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 StuPathalys Pharma announced a $150 million financing round led by Abingworth to fully fund Phase 3 clinical trials and pre-commercialization activities for its drug upacicalcet. The company simultaneously formed a strategic collaboration with Launch Therapeutics, which will lead the operational execution of these trials while Pathalys retains commercial rights outside Japan. This partnership aims to accelerate regulatory approval in the U.S. for treating secondary hyperparathyroidism in hemodialysis patients.VC News DailyPathalys Pharma Raises $150MPathalys Pharma announced a collaboration with Launch Therapeutics to advance phase 3 clinical trials for upacicalcet (PLS240), a treatment for secondary hyperparathyroidism in hemodialysis patients. The company raised $150 million through a combination of secured product financing and equity, with Abingworth leading both financings alongside Carlyle and OrbiMed. The funding will support the two phase 3 trials, registration efforts, and pre-commercialization activities.